Integrated Filing — IndAS



General information about company
Scrip Code 500257
NSE Symbol LUPIN
MSEI Symbol NOTLISTED
ISIN INE326A01037
Name of company Lupin Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 05-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 05-Aug-2025   17:00:00
End date and time of board meeting 05-Aug-2025   19:40:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party?
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.
Whether the company is a high value debt listed entity according to regulation 15 (1A)?
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?
Latest Date on which RPT policy is updated
Indicate Company website link for updated RPT policy of the Company
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclosure for the default on Loans and Debt Securities is not applicable to the Company.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 57085900000
Other income 541400000
Total income 57627300000
2 Expenses
(a) Cost of materials consumed 9091400000
(b) Purchases of stock-in-trade 3119300000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -397500000
(d) Employee benefit expense 6438900000
(e) Finance costs 189000000
(f) Depreciation, depletion and amortisation expense 1767300000
(f) Other Expenses
1 Other Expenses 12021900000 12021900000
2 Net (gain) / loss on foreign currency transactions -484500000 -484500000
Total other expenses 11537400000
Total expenses 31745800000
3 Total profit before exceptional items and tax 25881500000
4 Exceptional items 0
5 Total profit before tax 25881500000
6 Tax expense
7 Current tax 4515400000
8 Deferred tax 85400000
9 Total tax expenses 4600800000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 21280700000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 21280700000
17 Other comprehensive income net of taxes -19900000
18 Total Comprehensive Income for the period 21260800000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 913500000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 46.6
Diluted earnings (loss) per share from continuing operations 46.48
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 46.6
Diluted earnings (loss) per share from continuing and discontinued operations 46.48
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 05, 2025. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations & Disclosure Requiremen Regulations, 2015. n n2. During the current quarter, 151,078 equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs, resulting in an increase in the paid up equity share capital by Rs. 0.3 million and securities premium account by Rs. 146.1 million. n n3. Pursuant to the meeting of the Board of Directors held on held on February 11, 2025 and March 31, 2025, the Company has transferred its Over the Counter OTC business in India, with effect from July 1, 2025, to its wholly owned subsidiary Lupinlife Consumer Healthcare Limited, as a going concern on slump sale basis for a consideration of Rs. 8,200.0 million, subject to working capital adjustments. n n4. Pursuant to the meeting of the Board of Directors held on held on March 31, 2025, the Company has transferred its API RD Business in India, with effect from July 1, 2025, to its wholly owned subsidiary Lupin Manufacturing Solutions Limited, as a going concern on slump sale basis for a consideration of Rs. 180.0 million, subject to working capital adjustments. n n5. During the quarter ended June 30, 2024 and year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million Rs. 750.5 million in connection with the drug Glumetza without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. n n6. During the year ended March 31, 2025, the Company has made a provision of Rs. 856.1 million USD 10.0 million towards ongoing dispute. n n7. During the year ended March 31, 2025, the Company has provided for impairment in value of investment in subsidiaries of Rs. 772.2 million. n n8. During the quarter and year ended March 31, 2025, the Company has recognised an impairment charge of Rs. 410.9 million related to property, plant and equipment, commercialised intangibles and capital work in progress. n n9. Upon execution of the Business Transfer Agreement, the Company on July 01, 2024 had transferred its generic business in India to its wholly owned subsidiary Lupin Life Sciences Limited formerly known as Lupin Atharv Ability Limited, as a going concern on slump sale basis for a consideration of Rs. 1,100.0 million. n n10. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full previous financial year and the unaudited published year to date figures up to the third quarter ended December 31, 2024. The year to date figures up to the third quarter ended December 31, 2024 were only subject to Limited Review and not audited. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss -103500000 -103500000
Total Amount of items that will not be reclassified to profit and loss -103500000
2 Income tax relating to items that will not be reclassified to profit or loss -36200000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss 72800000 72800000
Total Amount of items that will be reclassified to profit and loss 72800000
4 Income tax relating to items that will be reclassified to profit or loss 25400000
5 Total Other comprehensive income -19900000